ED Assessment – Regulatory
Compliance & Risk Evaluation

Endocrine Disruptors (EDs) are substances that interfere with the hormonal system, potentially leading to adverse effects on human health and the environment. Their identification and regulation are of growing importance, particularly under REACH and the Biocidal Products Regulation (BPR).

Our Expertise in ED Assessment

At CFCS, we offer comprehensive support for ED evaluation and regulatory compliance

Scientific Expertise Our team has extensive experience in endocrine mode-of-action assessment.

Regulatory Know-How We support clients in navigating REACH Annex XV, BPR ED criteria, and evolving regulatory frameworks.

Tailored Solutions From screening to dossier defense, we adapt our approach to your specific needs.

Contact us today to discuss your ED assessment requirements.

Our expertise and services include:

Screening & Prioritisation
Evaluation of endocrine activity based on QSAR models, in vitro assays, and read-across Application of (Q)SAR tools and databases (e.g., OECD QSAR Toolbox, VEGA, etc.)

Weight-of-Evidence (WoE) Assessment
Analysis of existing data from toxicology, ecotoxicology, and mechanistic studies Identification of data gaps and recommendation of additional testing strategies

Regulatory Testing & Study Monitoring
OECD Level 2-5 assays for endocrine activity and adversity (e.g., OECD 443, 441, 455, 458) Coordination and monitoring of in vitro and in vivo studies

Regulatory Compliance & Dossier Preparation
Preparation of ED assessments for REACH and BPR dossiers Development of defense strategies for ECHA or national authorities